pharma · Hemophilia A · Hemophilia A or B With Inhibitors
Baxalta Innovations
Baxalta Innovations GmbH
Baxalta is a pharma organization headquartered in Illinois, USA. Primary therapeutic focus areas include Hemophilia A, Hemophilia A or B With Inhibitors, Congenital Thrombotic thrombocytopenic purpura (cTTP), Hereditary
Illinois, USA HQ
2015 Founded
475 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Illinois, USA
- Founded
- 2015
- Employees
- 475
- Programs
- 6
- Drugs
- 12
- Patents
- 1
TAK-755-3002
Phase 3 · small molecule · Congenital Thrombotic thrombocytopenic purpura (cTTP)
TAK-755-3002 for Congenital Thrombotic thrombocytopenic purpura (cTTP) is a Phase 3 program (small_molecule) at Baxalta Innovations GmbH with 1 ClinicalTrials.gov record(s).
Internal code TAK-755-3002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Baxalta Innovations GmbH
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Congenital Thrombotic thrombocytopenic purpura (cTTP)
- Status
- active
- Trials
- 1